Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.gastrohep.2021.11.011 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Exploring the Therapeutic Potential of Glucagon-Like Peptide 1 (GLP-1) Receptor Agonists in Polycystic Ovary Syndrome.
Cureus
November 2024
Obstetrics and Gynecology, Mount Sinai Medical Center, Miami Beach, USA.
Polycystic ovary syndrome (PCOS) is a complex endocrine disorder affecting women of reproductive age and is characterized by hormonal imbalances, insulin resistance, and reproductive dysfunctions. Glucagon-like peptide 1 (GLP-1) receptor agonists (GLP-1 RAs) are primarily used in diabetes management to enhance insulin release by stimulating GLP-1 receptors in the pancreas. The search strategy included randomized trials on the management of PCOS symptoms with GLP-1 RAs alone or in combination with other medications; meta-analyses, literature reviews, or case reports were excluded.
View Article and Find Full Text PDFQuinoa ameliorates polycystic ovary syndrome via regulating gut microbiota through PI3K/AKT/mTOR pathway and autophagy.
Nutr Metab (Lond)
October 2024
School of Traditional Chinese Medicine, Beijing University of Chinese Medicine, Beijing, 100029, China.
Article Synopsis
- The study investigates the effects of quinoa on polycystic ovary syndrome (PCOS), focusing on its influence on metabolic pathways (PI3K/AKT/mTOR), autophagy, and gut microbiota in PCOS-induced rats.
- Female rats were induced with PCOS using letrozole and then fed a quinoa diet for 8 weeks to assess changes in their estrous cycle, hormone levels, and tissue pathology.
- Results showed that quinoa improved the estrous cycle and biochemical indicators, regulated key proteins in the ovary, repaired intestinal barriers, and positively influenced gut microbiota, suggesting potential therapeutic benefits for PCOS.
Insulin Resistance, Obesity, and Lipotoxicity.
Adv Exp Med Biol
September 2024
Koç University Medical School, Section of Endocrinology and Metabolism, Koç University Hospital, Topkapi, Istanbul, Turkey.
Lipotoxicity, originally used to describe the destructive effects of excess fat accumulation on glucose metabolism, causes functional impairments in several metabolic pathways, both in adipose tissue and peripheral organs, like liver, heart, pancreas, and muscle. Ectopic lipid accumulation in the kidneys, liver, and heart has important clinical counterparts like diabetic nephropathy in type 2 diabetes mellitus, obesity-related glomerulopathy, nonalcoholic fatty liver disease, and cardiomyopathy. Insulin resistance due to lipotoxicity indirectly lead to reproductive system disorders, like polycystic ovary syndrome.
View Article and Find Full Text PDFThe interplay between oxidative stress, zinc, and metabolic dysfunction in polycystic ovarian syndrome.
Mol Cell Biochem
September 2024
Departments of Obstetrics and Gynecology, The C.S. Mott Center for Human Growth and Development, Wayne State University School of Medicine, Detroit, MI, 48201, USA.
Polycystic ovarian syndrome (PCOS) is a functional endocrine disorder characterized by hyperandrogenism, ovulatory dysfunction, and polycystic ovarian morphology that has been associated with chronic disease and comorbidities including adverse metabolic and cardiac disorders. This review aims to evaluate the role of oxidative stress and zinc in the metabolic dysfunction observed in PCOS, with a focus on insulin resistance. Recent studies indicate that oxidative stress markers are elevated in PCOS and correlate with hyperandrogenemia, obesity, and insulin resistance.
View Article and Find Full Text PDFClinical Effects of Glucagon-Like Peptide-1 Agonist Use for Weight Loss in Women With Polycystic Ovary Syndrome: A Scoping Review.
Cureus
August 2024
Family Medicine, Nova Southeastern University, Fort Lauderdale, USA.
Glucagon-like peptide-1 (GLP-1) is a gastrointestinal regulatory hormone that stimulates insulin release from the pancreas. While GLP-1 receptor agonists (GLP-1 RAs) have traditionally been utilized to address insulin resistance, their potential application in treating polycystic ovary syndrome (PCOS) has recently garnered attention. This study aimed to investigate the therapeutic efficacy of GLP-1 RAs use for weight loss in women diagnosed with PCOS.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!